19X Stock Overview
A biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Axsome Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$92.00 |
| 52 Week High | US$98.88 |
| 52 Week Low | US$59.06 |
| Beta | 1.25 |
| 11 Month Change | 13.30% |
| 3 Month Change | 13.27% |
| 1 Year Change | 50.47% |
| 33 Year Change | 210.92% |
| 5 Year Change | 126.60% |
| Change since IPO | 2,418.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| 19X | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 3.0% | 1.4% | 0.8% |
| 1Y | 50.5% | -18.4% | 9.1% |
Return vs Industry: 19X exceeded the German Pharmaceuticals industry which returned -18.4% over the past year.
Return vs Market: 19X exceeded the German Market which returned 9.1% over the past year.
Price Volatility
| 19X volatility | |
|---|---|
| 19X Average Weekly Movement | 6.8% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 19X has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 19X's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 607 | Herriot Tabuteau | www.axsome.com |
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder.
Axsome Therapeutics, Inc. Fundamentals Summary
| 19X fundamental statistics | |
|---|---|
| Market cap | €4.51b |
| Earnings (TTM) | -€296.84m |
| Revenue (TTM) | €323.09m |
14.0x
P/S Ratio-15.2x
P/E RatioIs 19X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 19X income statement (TTM) | |
|---|---|
| Revenue | US$338.46m |
| Cost of Revenue | US$30.17m |
| Gross Profit | US$308.29m |
| Other Expenses | US$619.25m |
| Earnings | -US$310.95m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.42 |
| Gross Margin | 91.09% |
| Net Profit Margin | -91.87% |
| Debt/Equity Ratio | 193.8% |
How did 19X perform over the long term?
See historical performance and comparison